Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.

Herbert Y. Meltzer*, Michael Davidson, Alexander H. Glassman, W. Victor R Vieweg

*Corresponding author for this work

Research output: Contribution to journalReview article

45 Scopus citations

Abstract

The atypical antipsychotic drugs are a major advance in the treatment of psychosis in spite of concerns about metabolic and cardiovascular side effects that affect morbidity and mortality. Concerns about weight gain, hypoglycemia, diabetes, and increases in lipids as well as sudden death due to torsades de pointes and other cardiovascular events can temper enthusiasm about the atypical antipsychotics. The challenge for the clinician is to weigh the benefits and risks for each drug for each patient and develop a treatment plan with the individual patient in mind. This article discusses both risks and benefits of antipsychotic treatment and presents a treatment algorithm to aid the clinician in choosing medications for the psychotic patient.

Original languageEnglish (US)
Pages (from-to)25-29
Number of pages5
JournalThe Journal of clinical psychiatry
Volume63 Suppl 9
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.'. Together they form a unique fingerprint.

  • Cite this